EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

CompletedOBSERVATIONAL
Enrollment

256

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

Trastuzumab deruxtecan

No drug will be administered during this study.

Trial Locations (21)

17007

ICO Girona, Girona

20089

Breast Center Humanitas Cancer Center IRCCS Istituto Clinico Humanitas, Rozzano

23007

Hospital Universitario de Jaen, Jaén

28040

Hospital Clínico San Carlos, Madrid

28041

Hospital 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

33081

Centro di riferimento Oncologico (CRO), National Cancer Institute, Aviano

35128

Institute Oncology Veneto, Padua

41013

Hospital Universitario Virgen del Rocio, Seville

46009

Fundacion Instituto Valenciano de Oncologia, Valencia

80131

National Cancer Instutute 'Fondazione Pascale, Naples

D04 N2EO

St. Vincent's Private Hospital, Dublin

D04 T6F4

St. Vincent's University Hospital, Dublin

00128

Universita Campus Bio-Medico Di Roma, Rome

00161

Policlinico Umberto I Di Roma, Rome

00168

Fondazione Policlinico Univeritario Agostino Gemeli, Rome

03010

Hospital General Universitario De Alicante, Alicante

08003

Hospital Del Mar, Barcelona

08023

Hospital Quiron Salud Barcelona, Barcelona

08035

Hospital Val d'Hebron, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY